Trends in Pharmacological Sciences

Article	Citations
Subscription and Copyright Information	670
Shearing of surface mucin saps tumor cell strength	571
Subscription and Copyright Information	279
Advisory Board and Contents	245
Subscription and Copyright Information	245
Subscription and Copyright Information	219
Subscription and Copyright Information	206
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	200
Structural asymmetry in FGF23 signaling	188
Muscarinic receptors: from clinic to bench to clinic	183
Cancer pathogenesis and phase targeting through condensate fragility	166
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	151
Swinging the SWI/SNF complexes for cancer therapy	147
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	140
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	139
Compstatins: the dawn of clinical C3-targeted complement inhibition	131
Targeting complement in neurodegeneration: challenges, risks, and strategies	125
Therapeutic inhibition of ferroptosis in neurodegenerative disease	114
Structural pharmacology and mechanisms of GLP-1R signaling	110
Advisory Board and Contents	106
Direct in vivo CAR T cell engineering	106
Engineering ACE2 decoy receptors to combat viral escapability	105
Leveraging human microbiomes for disease prediction and treatment	105
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	104
Advisory Board and Contents	103

HSV-1 as a gene delivery platform for cancer gene therapy	101
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	99
A smart hospital-driven approach to precision pharmacovigilance	95
Advisory Board and Contents	95
Programmable CAR immunotherapies for neurodegenerative proteinopathies	94
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	89
A deep dive into degrader-induced protein-protein interfaces	87
Phenotypic approaches for CNS drugs	87
A perspective on psychedelic teratogenicity: the utility of zebrafish models	85
Nemolizumab (Nemluvio®) for prurigo nodularis	84
Ribosome-directed cancer therapies: the tip of the iceberg?	76
Genetically engineered loaded extracellular vesicles for drug delivery	73
Optogenetic engineering for precision cancer immunotherapy	72
Subscription and Copyright Information	69
Thriving as members of under-represented groups in pharmacology-related careers	67
Emerging approaches to induce immune tolerance to therapeutic proteins	66
Mentoring future science leaders to thrive	66
Subscription and Copyright Information	66
Now you serine, now you don't	66
Subscription and Copyright Information	64
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	58
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	58
The structure, function, and pharmacology of MRGPRs	58
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	58
Advancing non-destructive analysis of 3D printed medicines	56
Bimetallic nanoadjuvants for cancer vaccines	56
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	55
Piezo1: structural pharmacology and mechanotransduction mechanisms	55
Suzetrigine for moderate to severe acute pain	53
Mechanistic insights into nitazenes at the μ-opioid receptor	52
Could dexmedetomidine be repurposed as a glymphatic enhancer?	50
Autologous, allogeneic, in vivo CAR for autoimmune diseases	49
Molecular glues evolve from serendipity to rational design	47
Targeting metabolic vulnerabilities with advanced delivery systems	43
The road less traveled: activating an oncogenic kinase	43
Advisory Board and Contents	43
Salt-inducible kinases: new players in pulmonary arterial hypertension?	42
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	42
The promise of targeted protein degradation approaches	42
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
Promising neuroimmune targets and drugs for CNS diseases	40
Advisory Board and Contents	40
Treg-directed cancer immunotherapy beyond immune checkpoints: progress and opportunities	40
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	40
Subscription and Copyright Information	39
Monkeypox: potential vaccine development strategies	38
PDE4 modulates muscle signaling in cancer cachexia	38
Advisory Board and Contents	38
A novel function of the M2 muscarinic receptor	37

Validation of agent-based models of surface receptor oligomerisation	37
Targeting the assembly of biomolecules: condensate-based drug discovery	36
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	36
The end of the beginning in understanding SLC22 polyspecificity	36
Protein acylations in cancer immunity: effects and therapeutic opportunities	36
Decoding pseudouridine: an emerging target for therapeutic development	35
BTK inhibitors: past, present, and future	33
Artificial intelligence in rare diseases: toward clinical impact	33
Frizzleds act as dynamic pharmacological entities	33
Tackling microbial iron homeostasis: novel antimicrobial strategies	33
Advisory Board and Contents	32
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	31
Advisory Board and Contents	30
Subscription and Copyright Information	30
Demographic diversity in platelet function and response to antiplatelet therapy	29
Metabolic regulation in normal and leukemic stem cells	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
GPR35: from enigma to therapeutic target	29
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	29
Topical difamilast for the treatment of mild-to-moderate atopic dermatitis	29
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	28
Development of PROTACs using computational approaches	28
Recent advances in generative biology for biotherapeutic discovery	28
Eflornithine for treatment of high-risk neuroblastoma	28
Subscription and Copyright Information	27
Subscription and Copyright Information	27
Tackling chronic kidney disease in diabetic patients with finerenone	27
Targeting plasma membrane cholesterol as a novel anticancer therapy	26
A novel anticancer pharmacological agent targeting mitochondrial complex I	26
Biologics and cardiac disease: challenges and opportunities	26
Visceral obesity and HFpEF: targets and therapeutic opportunities	26
Subscription and Copyright Information	26
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	26
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	25
Recent advancements in vaccine research and development	24
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	24
Boosting CAR-T cell therapy through vaccine synergy	24
Neutrophil extracellular traps in wound healing	24
Harnessing associative learning paradigms to optimize drug treatment	24
Subscription and Copyright Information	24
The structure, function, and pharmacology of SK channel family	24
Targeting sensory neuron GPCRs for peripheral neuropathic pain	24
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	23
Circadian biology to advance therapeutics for mood disorders	23
Taming PRMT5–adaptor protein interactions	23
Challenges and opportunities associated with rare-variant pharmacogenomics	22
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	22
Therapeutic antibodies targeting G protein-coupled receptors	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	22
NLRP3 and pyroptosis blockers for treating inflammatory diseases	21
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	21
The ABCs of psychedelics: a preclinical roadmap for drug discovery	20
Targeted protein degrader development for cancer: advances, challenges, and opportunities	20
Targeting competitive Fe–S regulation to treat Friedreich’s ataxia	20
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	20
Subscription and Copyright Information	20
Advisory Board and Contents	20
Odorant receptors as potential drug targets	19
The structure and function of YTHDF epitranscriptomic m6A readers	19
Potential for targeting small heat shock protein modifications	19
GPCR-dependent and -independent arrestin signaling	18
Malolactone strikes: K-Ras-G12D's Achilles' heel	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
β-Arrestins and disease-linked variants: opportunities for targeted modulation	18
Targeting peptide–HLA complexes for precision immunotherapy	18
Advisory Board and Contents	18
Subscription and Copyright Information	18
Glymphatic-stagnated edema induced by traumatic brain injury	18
Advisory Board and Contents	18
Drugging cold-response networks for neuroprotection	18
Induced proximity for dephosphorylation	18
Thapsigargin: key to new host-directed coronavirus antivirals?	17
Leveraging non-enzymatic functions of LSD1 for novel therapeutics	17
Bridging the gap in neuropsychiatric translational research	17
Advancing small-molecule drug discovery by encoded dual-display technologies	16
Advisory Board and Contents	16
Harnessing deep learning for enhanced ligand docking	16
Targeting ion channel dysregulation in tumors: emerging therapeutic opportunities	16
Glaucoma: neuroprotection with NAD-based therapeutic interventions	15

NET-targeted therapy: effects, limitations, and potential strategies to enhance treatment efficacy	15
Advisory Board and Contents	15
Endometriosis: cannabidiol therapy for symptom relief	15
Electroceuticals: emerging applications beyond the nervous system and excitable tissues	15
Celiac disease: mechanisms and emerging therapeutics	15
Advisory Board and Contents	15
Subscription and Copyright Information	15
Mitochondrial dynamics proteins as emerging drug targets	15
Emerging epigenetic insights into aging mechanisms and interventions	15
Isoform-selective targeting of PI3K: time to consider new opportunities?	15
Fluorescent RNAs: new opportunities for drug discovery	14
Subtyping for pancreatic cancer precision therapy	14
Nanodelivery of cGAS-STING activators for tumor immunotherapy	14
Advisory Board and Contents	14
Multiple hERG channel blocking pathways: implications for macromolecules	14
Current landscape of preclinical models of diabetic cardiomyopathy	14
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	14
A mechanism for ligand-dependent activation of AHR	14
Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation	14
Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics	14
Advisory Board and Contents	14
Targeting glycosylation to enhance tumor immunotherapy	14
Click chemistry charts covalent drug landscapes in vivo	13
TNIK’s emerging role in cancer, metabolism, and age-related diseases	13
Present and future of microglial pharmacology	13
At last: the mitochondrial pyruvate carrier structure revealed!	13
Engineering extracellular vesicles for diagnosis and therapy	13
Halting neuron–fibroblast crosstalk disarms tumor and augments immunotherapy	13
Targeting the senescence–autophagy axis for idiopathic pulmonary fibrosis therapy	13
Targeting galectin-3 in inflammatory and fibrotic diseases	12
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	12
Targeting chromosomal instability and aneuploidy in cancer	12
IRAK4: potential therapeutic target for airway disease exacerbations	12
Advisory Board and Contents	12
Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation	12
Photoswitchable allosteric and dualsteric ligands in GPCR pharmacology	12
Advisory Board and Contents	11
Small molecule modulation of organelle membrane contact sites	11
Emerging mechanisms of psilocybin-induced neuroplasticity	11
Subscription and Copyright Information	11
Casimersen for the treatment of Duchenne muscular dystrophy	11
18F-Flurpiridaz PET for imaging of myocardial ischemia	10
Fezolinetant for menopausal hot flashes and night sweats	10
Giving ERK a jERK from the endosome	10
Structural snapshot of a β-arrestin-biased receptor	10
Therapeutic targeting of exportin-1 beyond nuclear export	10
February 2026 issue first authors	10
Neuron–tumor crosstalk fuels small cell lung cancer	10
Heterobifunctional small molecules to modulate RNA function	10
Subscription and Copyright Information	9
Siglecs in immunotherapy: current clinical landscape and prospects	9
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	9
Targeting the sensory–sympathetic axis for cancer immunotherapy	9
Repurposing trifluoperazine for glioblastoma treatment	9
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	9
Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development	9
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities	9
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	9
Targeting neurological abnormalities in lysosomal storage diseases	8
PPAR agonists for the treatment of neuroinflammatory diseases	8
The structure and function of olfactory receptors	8
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment	8
Gut-derived brain T cells modulate behavior via IFN-γ	8
March 2026 issue first authors	8
Targeting TRPM channels for cerebral ischemia–reperfusion injury	8
Beyond the blood–brain barrier: the fate of transcytosed therapeutics	8
Potentiation of GPCR signaling by ATP and sugar monophosphates	8
Subscription and Copyright Information	8
Data-quality-guided AI strategies for natural product drug discovery	8
VMAT structures reveal exciting targets for drug development	8
Emerging paradigms and recent progress in targeting ErbB in cancers	8
Some assembly required: a single-RNA vaccine against enterovirus-D68	8
A quick guide to networking for scientists	8
Subscription and Copyright Information	7
A decoy mutant ACE2 designed to reduce COVID-19	7
Targeting Fks1 proteins for novel antifungal drug discovery	7
PSA inhibitors for contraception: insights from prostate cancer	7
Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine	7
Mutated G proteins as drug targets	7
Enhancing oncogenic signaling to kill cancer cells	7
Human carbonic anhydrase modulators: the past, present, and future	7
Data and AI-driven synthetic binding protein discovery	7
Emerging mechanisms and therapeutics in inflammatory muscle diseases	7
Design and development of glucocorticoid receptor modulators	7
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies	7
Pharmacogenomics in treatment of depression and psychosis: an update	7
Advances in cell therapy: progress and challenges in hematological and solid tumors	7
Hypothalamic AMPK as a possible target for energy balance-related diseases	7
ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics	7
The future of neuroimmunology research for CNS disease therapeutics	6
Formyl peptide receptors as therapeutic targets in eye disease	6
Shining light on parvalbumin interneuron plasticity	6
Transforming the drug discovery landscape	6
Advisory Board and Contents	6
Leveraging conformational ensembles in allosteric drug discovery	6